Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 17/20 | 0.52 |
| ▸ | SCTR | P47872 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556880 | 0.92 | GLP1R (0.57) | GLP1RSCTRTFPI | |
| SCHEMBL30262188 | 0.91 | GLP1R (0.59) | GLP1RSCTRTFPI | |
| SCHEMBL31211763 | 0.88 | KEAP1 (0.57) | GLP1RSCTRKEAP1 | |
| SCHEMBL31211842 | 0.88 | KEAP1 (0.57) | GLP1RSCTRKEAP1 | |
| SCHEMBL30883242 | 0.88 | GLP1R (0.56) | GLP1RSCTRTFPI | |
| SCHEMBL30974518 | 0.87 | TFPI (0.62) | GLP1RSCTRTFPI | |
| SCHEMBL29822692 | 0.87 | GLP1R (0.59) | GLP1RSCTRKEAP1 | |
| SCHEMBL29964770 | 0.87 | GLP1R (0.50) | GLP1RSCTRKEAP1TFPI | |
| SCHEMBL31307934 | 0.87 | GLP1R (0.56) | GLP1RSCTRKEAP1 | |
| SCHEMBL31182582 | 0.86 | PTH1R (0.61) | GLP1RSCTRKEAP1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240122847-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | LONZA AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-114026213-A | Continuous blade type impeller | 龙沙有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | GLP1R 319/4885SCTR 126/4885KEAP1 3540/4885 |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | GLP1R 4287/4885SCTR 3272/4885KEAP1 4540/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | GLP1R 4/4885SCTR 343/4885KEAP1 4587/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | GLP1R 116/4885SCTR 169/4885KEAP1 1438/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | GLP1R 139/4885SCTR 668/4885KEAP1 3609/4885 |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | MRPL21, SET, RPS27A | GLP1R 1351/4885SCTR 130/4885KEAP1 3941/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | GLP1R 1/4885SCTR 11/4885KEAP1 4825/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | GLP1R 228/4885SCTR 489/4885KEAP1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.